What is included in the instructions for Betel/Bicizumab

Bimekizumab (Bimekizumab) is a new generation of biological agent for the treatment of plaque psoriasis. Its instructions detail the pharmacological properties, indications, usage, precautions and potential adverse reactions of the drug to help doctors and patients use the drug more scientifically and safely.

1. Basic information about drugs

Generic name: Bimekizumab（Bimekizumab）

Product name: Bimzelx

Type of drug: humanizedIgG1 monoclonal antibody

Main target: simultaneous inhibitionIL-17A and IL-17F

Dosage form and specification: injection,160mg/1mL, usually sold in single or double packages

Mechanism of action: By targeting and neutralizing pro-inflammatory cytokinesIL-17A and IL-17F, it reduces skin inflammatory response and improves psoriasis skin lesions.

2. Description of indications

Main Indications: For the treatment of adults with moderate to severe plaque psoriasis, particularly those who have had an inadequate response to or are intolerant to conventional systemic treatments (e.g., methotrexate, cyclosporine) or phototherapy.

3. Instructions for usage and dosage

Recommended dosage: Each time 320mg (i.e. two 160mg injections), subcutaneous injection.

Initial period: A total of 5 injections at 0, 4, 8, 12 and 16 weeks.

Maintenance period: Starting from week 16, 320mg is injected every 8 weeks.

For patients whose weight is ≥120kg: after the 16th week, it is recommended to inject 320mg every 4 weeks to maintain blood concentration and efficacy.

Injection method: subcutaneous injection, which can be performed by medical personnel or self-injected by patients after professional training.

4. Contraindications and warning information

Main contraindications: patients with active infection (especially tuberculosis); those who are allergic to the active ingredients or excipients of this product

Pre-use screening: All patients should undergo tuberculosis screening and liver function assessment before taking the drug, and if necessary, receive treatment for tuberculosis first.

Contraindicated in pregnant women and lactating women: Due to the lack of sufficient human research data, it is recommended that it be used with caution or prohibited during pregnancy and lactating women.

5. Adverse reactions and countermeasures

Common side effects: oral fungal infection (such as thrush); upper respiratory tract infection (nasopharyngitis); redness, swelling or itching at the injection site; headache, fatigue; mild gastrointestinal discomfort

6. Storage conditions and instructions for use

Storage conditions: should be stored refrigerated at 2°C-8°C;

Avoid freezing and do not expose to high temperatures or direct sunlight; use as soon as possible after opening

Validity period: It is marked on the package. Use within the validity period. Injection is prohibited after the expiration date.

As an innovative targeted biological agent in the field of plaque psoriasis treatment in recent years, bichizumab's instructions not only cover the basic pharmacological mechanism, indications and standardized medication regimens, but also emphasize safety monitoring and individualized treatment management.

With its unique dual antagonism of IL-17A and IL-17F, bicizumab clinically demonstrates rapid onset of action, high skin lesion clearance rate and good long-term relief properties. With the gradual promotion of use in China and the progress of medical insurance negotiations, bichizumab is expected to bring better and more precise treatment options to more psoriasis patients in the future.

Reference materials:https://www.drugs.com/bimekizumab.html